Skip to content

Clinical Study on the Enhanced Antitumor Effect of Fecal Microbiota Transplantation Combined with Chemotherapy in Gastrointestinal Tumors: Exploration of the Mechanism of Synergy and Translational Pathways

Clinical Study on the Enhanced Antitumor Effect of Fecal Microbiota Transplantation Combined with Chemotherapy in Gastrointestinal Tumors: Exploration of the Mechanism of Synergy and Translational Pathways - Fecal Microbiota Transplantation in Enhancing Efficacy and Reducing Toxicity of Standard Therapy for Gastrointestinal Malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119498
Enrollment
Unknown
Registered
2026-02-28
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive tract tumors require treatment by the oncology department, which may include chemotherapy, targeted therapy or immunotherapy.

Interventions

Standard Oncology Treatment Group
Standard Oncology Treatment Combined with FMT Group:FMT
Control:None

Sponsors

Tianjin Third Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with digestive tract tumors diagnosed by histopathology of tissue/cells; 2.Have not received FMT and have not used drugs significantly affecting the microbiota (such as antibiotics) within the past 3 months; 3.Aged between 18 and 75; 4.Expected survival period greater than 3 months;

Exclusion criteria

Exclusion criteria: 1.Pregnant women, lactating women, individuals under the age of 18; 2.Comorbid severe diseases: organ failure (heart, lungs, liver, kidneys) or uncontrolled hypertension, diabetes; 3.Active infections: such as hepatitis B, hepatitis C, HIV, tuberculosis, etc; 4.Mental disorders: unable to understand the study or cooperate with treatment; 5.Other tumors: combined with other malignant tumors or severe blood/disease auto-immune diseases; 6.Unable to tolerate: unable to tolerate chemotherapy in advanced tumor stage;

Design outcomes

Primary

MeasureTime frame
Objective response rate, ORR;

Secondary

MeasureTime frame
Liver and kidney function;

Countries

China

Contacts

Public ContactJingjing Wang

Tianjin Third Central Hospital

wangjingjing0204@163.com+86 22 8411 2249

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026